Immutep Limited (IMM-AU)
Door re-opens to first efiltigimod alpha approval

KEY TAKEAWAY

Newly released overall survival ("OS") data from Immutep's Phase IIb AIPAC study in metastatic breast cancer ("mBC") shows efiltigimod alpha ("efti") chemotherapy combination meaningfully benefits subgroups representing >60% of the patient population. In patients <65 years or with low starting monocyte count efti plus paclitaxel increased OS by +7.1 months and +9.4 months respectively, in comparison to paclitaxel plus placebo (p<0.05). CD8 T cell analysis saw a sustained elevation in the efti group compared with prolonged OS. Given other clinical benefits evident across the whole patient population and efti's established safety, these data could be sufficient for regulatory approval in mBC; discussions with US and European regulators are prioritised. The data could also open the door to efti-chemo combination in other cancers such as NSCLC. On this basis, we reiterate our OUTPERFORM recommendation with an increased TP of AUD 0.90 (was AUD 0.61)

Basis for regulatory approval - With a median OS of 20.2 months after efti + paclitaxel treatment vs. 17.5 months with paclitaxel alone, there was a positive trend across the study population (p=0.14). There was a statistically significant rise c.50% from 14.8 to 21.9 months with efti vs. placebo (p=0.012) in patients <65yrs. Patients recruited with diminished immune function (baseline monocytes <0.25x10^9 cells/L) demonstrated 74% longer survival with efti vs. placebo (22.4 months vs. 12.9 months p=0.020). Subjects with more aggressive Luminal B type disease also showed improved OS (+3.8 months, p=0.077). With 40% of events still to report the trial could close mid-2021E. The clear impact on OS in subgroups, the safety of the drug and wider benefits across the patient population described below may provide a strong basis for provisional marketing approval.

Benefits apparent across whole patient population - In contrast to the unchanged 7.3 month progression free survival ("PFS"), overall response rate and disease control rate were 10% higher with efti (48.3% vs. 38.4% and 85.1% vs. 75.9% respectively), although not statistically significant. Also, while quality of life scores deteriorated at week 25 with placebo, this was not the case with efti, indicating an improved patient burden. The absence of OS reduction in efti compared to placebo following CDK4/6 therapy is also of note given the therapy's increasing use. These data indicate real benefits of efti to the whole patient population. Given overall improvements in PFS observed with efti in the first seven months when patients received chemo, benefits to the whole patient population could be extended by adopting a longer chemo regimen; more in line with the normal US standard of care; likely in the planned EOC Pharma China trial.

Potential to extend efti-chemo into other cancers - Synergy with the paclitaxel chemotherapy implies that the efti effect may be enhanced by the presence of a sustained 'co-inflammatory' stimulus. Maintaining chemo throughout efti treatment, as might be expected in US protocols could extend OS benefits to all patients. Given its good safety and tolerability, this may have implications in extending the benefits of efti in other indications such as NSCLC where an efti / chemo combo seems an obvious next step. This could also drive the exploration of other inflammatory / immune stimulating combinations such as radiotherapy.

Approved plans for China trial – EOC Pharma, Immutep's partner for efti development in China, announced the NMPA has approved Phase II trial mirroring the AIPAC design for efti + paclitaxel. Fully funded by EOC Pharma, this study aims to recruit 152 patients. Successful development of efti in China could generate substantial royalties and milestones; and treatment option for c.1.6m women p.a. in China.

Substantial additional upside - Assuming 45% probability for approval for mBC during 2021E, our risk adjusted sum-of-the-parts valuation of efti and other pipeline assets, indicates a fair value per share of AUD 0.9 rising to AUD 1.30 on mBC approval.
COMPANY DESCRIPTION

Immutep (known as Prima BioMed until November 2017) is an Australian clinical-stage biotechnology company that develops immunotherapies for cancer and autoimmune diseases. Immutep is the global leader in the understanding of and in developing therapeutics that modulate Lymphocyte Activation Gene-3 ("LAG-3"). LAG-3 was discovered in 1990 at the Institut Gustave Roussy by Dr Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer. The company has three assets in clinical and one asset in preclinical development. The lead product candidate is etflagimod alpha ("efti"), a first-in-class antigen presenting cell ("APC") activator being investigated in combination with chemotherapy or immune therapy for advanced breast cancer and melanoma. Immutep is dual-listed on the Australian Stock Exchange ("IMM") and on the NASDAQ Global Market ("IMMP") in the US (American Depository Receipts), and has operations in Europe, Australia, and the US. The company has licensing deals with Novartis, GSK and EOC (China only), and clinical trial collaboration and supply agreements with Merck & Co. and Merck KGaA / Pfizer, the latter for lead asset efti.

SCENARIOS

Base Case - GP Investment Case
Immutep generates further clinical data on efti and secures an outlicensing deal over the next 12 - 18 months.

Bluesky Scenario
N/A

Downside risk
Company is unable to generate further positive data on efti and fails to achieve licensing deal.

Peer Group Analysis

SWOT

Strengths: Increasing data supports use of efti in oncology combos. Leader in the understanding of LAG-3; broadest LAG-3 focused pipeline; validation from large pharma partners (Novartis, GSK, Merck & Co.); funded for >12 months.

Weaknesses: One single asset (eftilagimod alpha) accounts for the lion share of value; efti has not demonstrated convincing efficacy in monotherapy settings; efti is protected mainly by use and formulation patents, as the composition of matter patent has already expired.

Opportunities: LAG-3 could become the third pillar in immune checkpoint therapy and efti is the most advanced LAG-3 focused asset; efti could be the first immuno-oncology drug to be approved for metastatic breast cancer; oncology drugs addressing high unmet needs often enjoy shorter development and approval timelines than therapeutics in other disease areas; significant M&A activity in the immuno-oncology space.

Threats: EMA and FDA raise the hurdles for immunotherapy drugs.

INDUSTRY EXPECTATIONS

Immutep is developing immunotherapies for cancer, with a focus on the immune checkpoint LAG-3. The immune checkpoint inhibitor ("ICI") class has experienced rapid adoption since the launch of BMS’s Yervoy (ipilimumab) in 2011, owing to their ability to elicit durable responses in 20 - 50% of patients for up to 10 years. The global ICI market was worth $16.8bn in 2018 and is expected to nearly triple by 2022E, driven largely by expanding use of existing therapies both in approved and new indications. The race is on to develop novel compounds with complementary mechanisms of action for combination therapy able to augment response rate without increasing toxicity, which, if successful, are expected to enjoy rapid uptake.
Important Disclosures: Non-Independent Research

Analyst Certification
I, Dr. Chris Redhead, hereby certify that the views regarding the companies and their securities expressed in this research report are accurate and are truly held. I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this research report.

Meaning of goetzpartners Research Ratings
goetzpartners securities Limited ("GPSL") publishes investment recommendations, which reflect the analyst’s assessment of a stock’s potential relative return. Our research offers 4 recommendations or ‘ratings’:

OUTPERFORM - Describes stocks that we expect to provide a relative return (price appreciation plus yield) of 15% or more within a 12-month period.
NEUTRAL - Describes stocks that we expect to provide a relative return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.
UNDERPERFORM - Describes stocks that we expect to provide a relative negative return (price appreciation plus yield) of 10% or more within a 12-month period.
NON-RATED – Describes stocks on which we provide general discussion and analysis of both up and downside risks but on which we do not give an investment recommendation.

Companies Mentioned in this report
• Immutep Limited (IMM-AU)

Valuation Methodology
GPSL’s methodology for assigning recommendations may include the following: market capitalisation, maturity, growth / value, volatility and expected total return over the next 12 months. The target prices are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

Frequency
This research will be reviewed at a frequency of 3 months. Any major changes to the planned frequency of coverage will be highlighted in future research reports.

Conflicts of interest
GPSL is required to disclose any conflicts of interest which may impair the firm’s objectivity with respect to any research recommendations contained herein. Please click on the link to view the latest version of our Conflicts of Interest policy.

We are also required to disclose any shareholdings of the firm or our affiliates in any relevant issuers which exceed 5% of the total issued share capital or any other significant financial interests held:

GPSL shareholdings in relevant issuers >5% - None.

GPSL wishes to disclose that it is party to a formal client agreement with Immutep Limited relating to the provision of advice and equity research services.

To avoid potential conflicts of interest arising, restrictions on personal account dealing are placed on analysts and other staff. The firm’s personal account dealing policy expressly prohibits staff and / or relevant connected persons from dealing in the securities of a relevant issuer. Analysts must not trade in a manner contrary to their published recommendation or deal ahead of the publicaion of any research report.

If our contractual relationship with a client ceases, then please be advised that GPSL will no longer publish equity research on the specific client and any recipients of our equity research publications should not rely on our forecasts / valuation that have previously been published in the last full company research publication. Please note that GPSL will not publish a cessation of coverage notice to the market. Also, in accordance with the provision of MiFID2 – if any of our clients are not contractually paying GPSL to write and publish equity research, then we will not publish any future equity research publications to the market on the issuer until all of our unpaid fees have been fully paid.

To comply with the regulatory requirement to disclose. We disclose the monthly proportion of recommendations that are OUTPERFORM, NEUTRAL, UNDERPERFORM and NON-RATED. We also disclose a summary of the history of our analysts’ investment recommendations (in accordance with EU MAR rules effective 3rd July 2016). goetzpartners publishes this information on the following link: Research Summary.

Country-Specific Disclosures
United Kingdom: goetzpartners securities Limited ("GPSL") is authorised and regulated by the Financial Conduct Authority ("FCA"); registered in England and Wales No. 04684144; Registered Office / Address: The Stanley Building, 7 Pancras Square, London, N1C 4AG.
Risks

This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5). Information relating to any company or security is for information purposes only and should not be interpreted as a solicitation to buy or sell any security or to make any investment. The information in this research report has been compiled from sources believed to be reliable, but it has not been independently verified. No representation is made as to its accuracy or completeness, no reliance should be placed on it and no liability is accepted for any loss arising from reliance on it, except to the extent required by the applicable law. All expressions of opinion are subject to change without notice. Opinions, projections, forecasts or estimates may be personal to the author and may not reflect the opinions of goetzpartners securities Limited ("GPSL"). They reflect only the current views of the author at the date of the research report and are subject to change without notice. GPSL’s research reports are not intended for Retail Clients as defined by the FCA. This research report is intended for professional clients only. Research reports are for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. The analysis, opinions, projections, forecasts and estimates expressed in research reports were not independently produced or selected. The analysis and opinions expressed herein are based upon the research and analyses of the research analyst(s). The research analyst(s) may or may not have invested in or have any intention of investing in any security discussed in the research report.

The authors of research reports benefit financially from the overall success of GPSL. The independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. GPSL is authorised and regulated in the United Kingdom by the FCA in connection with its distribution and for the conduct of its investment business in the European Economic Area. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients. Persons who are unsure of which investor category applies to them should seek professional advice before placing reliance upon or acting upon any of the recommendations contained herein.

Other EU Investors: This research report has been prepared and distributed by GPSL. This research report is a marketing communication for the purposes of Directive 2004/39/EC (MiFID). It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. GPSL is authorised and regulated in the United Kingdom by the FCA in connection with its distribution and for the conduct of its investment business in the European Economic Area. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients. Persons who are unsure of which investor category applies to them should seek professional advice before placing reliance upon or acting upon any of the recommendations contained herein.

U.S. PERSONS: This research report has been prepared by GPSL, which is authorised to engage in securities activities in England and Wales and to conduct designated investment business in the European Economic Area. GPSL is not a registered broker-dealer in the United States of America and therefore is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution in the United States solely to “major U.S. institutional investors” as defined in Rule 15a-6 under the Securities Exchange Act of 1934.

Other countries: Laws and regulations of other countries may also restrict the distribution of this research report. Persons in possession of research publications should inform themselves about possible legal restrictions and observe them accordingly.

This is a marketing communication. For professional investors and institutional use only. The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5). GPSL is authorised and regulated by the Financial Conduct Authority (FRN 225563). GPSL does and seeks to do business with companies / issuers covered in its research reports. As a result, investors should beware that GPSL may have a conflict of interest that could affect the objectivity of this research report. Investors should consider this research report as only a single factor in making their investment decision. GPSL has a formal client relationship with Immutep Limited.
large falls in their value which may cause losses. Some of the information or data in this research report may rely on figures denominated in a currency other than that of GBP (the currency should be stated), the return may increase or decrease as a result of currency fluctuations. International investment includes risks related to political and economic uncertainties of foreign countries, as well as currency risk. To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of research reports or their contents.

GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they are monitored for regulatory and training purposes.

Compensation
GPSL has received compensation from Immutep Limited for the provision of research and advisory services within the previous twelve months.

IMM-AU
AUD0.900  |  Company Update
14 December 2020

goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
Tel: +44 (0)203 859 7725
www.goetzpartnerssecurities.com